Harness Dickey
  • COVID-19 IP Update
  • People
  • Global IP Services
    • Practice Areas
    • Industries
    • Case Studies
  • Blog
  • News & Awards
  • About Us
    • Careers
    • Offices
  • Contact Us
  • Client Login

Blog

Subscribe to our Blogs

  • Subscribe to our Blogs

Our business model is to cultivate lawyers who know all there is to know about intellectual property, whether it be special requirements under the America Invents Act (AIA), patenting chemical compositions and pharmaceuticals, current developments in software patenting, or combating “bad patents” in federal court litigation.  Lawyers from our various practice groups enjoy sharing their views in our blogs. Please join our audience and help us enrich the discussion. We welcome your participation and insight.

  • Chemistry & Nanotechnology

      ALL CATEGORIES

      • Biologics & Biosimilars
        • Antitrust Issues
        • Competitor Dynamics
        • FDA Guidance & Updates
        • Interchangeability
      • BioPharma
      • Chemistry & Nanotechnology
      • COVID-19 IP Update
      • IP Management
      • IPR-PGR
      • Litigation
      • Patent Prosecution
      • quIPs
      • Trademarks
  • All Years
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
  • Authors
    • John H. Ambrose, Jr.John H. Ambrose, Jr. 2
    • Jewell N. BriggsJewell N. Briggs 8
    • Elizabeth K. BrockElizabeth K. Brock 7
    • Christopher M. CaubleChristopher M. Cauble 1
    • William J. CoughlinWilliam J. Coughlin 1
    • Matthew L. CutlerMatthew L. Cutler 15
    • Donald J. DaleyDonald J. Daley 1
    • Nicholas S. DrysdaleNicholas S. Drysdale 7
    • Monte L. FalcoffMonte L. Falcoff 2
    • Glenn E. ForbisGlenn E. Forbis 11
    • Michael GambleMichael Gamble 1
    • Jason A. HeistJason A. Heist 1
    • Michael P. KellaMichael P. Kella 1
    • Hemant M. KeskarHemant M. Keskar 4
    • Sung Pil KimSung Pil Kim 1
    • Elisabeth A. KoralElisabeth A. Koral 10
    • Damian H. Kotsis, Ph.D.Damian H. Kotsis, Ph.D. 4
    • Kisuk LeeKisuk Lee 1
    • Robert J. LenihanRobert J. Lenihan 1
    • Chris K. MillerChris K. Miller 1
    • Michael R. NyeMichael R. Nye 4
    • Joshua A. PartingtonJoshua A. Partington 4
    • Leanne M. RakersLeanne M. Rakers 15
    • Douglas A. RobinsonDouglas A. Robinson 15
    • Joel R. SamuelsJoel R. Samuels 15
    • Jeffrey L. SnyderJeffrey L. Snyder 1
    • David L. SuterDavid L. Suter 2
    • Michael L. TaylorMichael L. Taylor 1
    • Jennifer R. TurchynJennifer R. Turchyn 4
    • Michael VarcoMichael Varco 3
    • Joseph E. Walsh, Jr.Joseph E. Walsh, Jr. 1
    • Andrew M. WaxmanAndrew M. Waxman 2
    • Bryan K. WheelockBryan K. Wheelock 15
    • Jennifer M. Woodside WojtalaJennifer M. Woodside Wojtala 12
    • Scott E. YackeyScott E. Yackey 1
    • Paul E. Zarek, Ph.D.Paul E. Zarek, Ph.D. 3
  • Harness Dickey Trademark Attorneys St. Louis Detroit Dallas Washington, DC

    July 27, 2020

    Apparent Agreement Did Not Protect Condom Company from Attack

    More

  • The Next Generation of Patent Attorneys

    July 22, 2020

    PTAB is not Limited to § 102 and § 103 when Reviewing Amended Claims in IPR

    More

  • IP Litigation and Contested Matters

    July 14, 2020

    Licensee’s Failure to Mark Ruined Patent Owner’s Claim for $3.5 Million in Pre-Suit Damages

    More

  • July 14, 2020

    Collaboration and Concerted Effort are What Result in Joint Inventorship

    More

  • July 9, 2020

    Over-designation of Confidential Information Costs Plaintiff Protection

    More

  • photo of biosimilar medications

    July 6, 2020

    42 U.S.C. § 262(l)(8) Simply Requires 180 Day Notice before Sale of a Biosimilar Product

    More

June 19, 2017

Missed opportunity: Federal Circuit Again Offers No Clarifying Insight on Alice’s Two-Step Framework

By: Jewell N. Briggs, Associate

April 28, 2017

Ready, Set, Nano-Race!

By: Jennifer M. Woodside Wojtala, Principal

Chemical Patents Image

March 2, 2017

Chemistry & Nanotechnology Developments to Watch in 2017

By: Jennifer M. Woodside Wojtala, Principal; Leanne M. Rakers, Principal

Harness Dickey Biopharma Patent Law

February 9, 2017

2016’s Top Patent and Trade Secret Developments for Chemistry and Nanotechnology

By: David L. Suter, Principal; Jennifer M. Woodside Wojtala, Principal; Jewell N. Briggs, Associate; Damian H. Kotsis, Ph.D., Associate; Jennifer R. Turchyn, Associate

Harness Dickey Biopharma Patent Law

February 9, 2017

USPTO Claim Construction Standards for Inter Partes Review Proceedings

By:

Harness Dickey Biopharma Patent Law

February 9, 2017

USPTO Standards of Review for Inter Partes Review Proceedings

By:

Harness Dickey Biopharma Patent Law

February 9, 2017

USPTO Errs in Failing to Carry Burden to Support Rejection

By:

Harness Dickey Biopharma Patent Law

February 9, 2017

On-Sale Bar for Contractor and Supplier Activities

By: Jennifer M. Woodside Wojtala, Principal; Jason A. Heist, Principal

Harness Dickey Biopharma Patent Law

February 9, 2017

Federal Trade Secrets Act

By: Jennifer M. Woodside Wojtala, Principal; David L. Suter, Principal; Jewell N. Briggs, Associate

Harness Dickey Biopharma Patent Law

February 9, 2017

Enhanced Damages for Willful Infringement

By: Damian H. Kotsis, Ph.D., Associate; Jennifer R. Turchyn, Associate

Stay current

  • Subscribe to our Blogs
  • Twitter
  • Facebook
  • LinkedIn
    • Sitemap
    • Privacy Statement
    • Legal Notice

  • © 2020 Harness, Dickey & Pierce, P.L.C. All rights reserved.